GlaxoSmithKline has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for albiglutide, under the brand name Eperzan, for treatment of type 2 diabetes.
CLICK ON TITLE
GSK’s diabetes drug Eperzan moves towards approval in Europe
Filed under: EU PIPELINE Tagged: albiglutide
